PPT-Ticagrelor compared with clopidogrel in patients with acute

PLAT elet Inhibition and patient O utcomes trial Outcomes in patients with a Planned Invasive Strategy The PLATO trial was funded by AstraZeneca Invasive PLATO background In STEMI and UANSTEMI current guidelines recommend 12 months of aspirin and clopidogrel. Antiplatelet Guidelines. PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY. Working Group: . James D. Douketis MD, FRCP(C); A. Graham . Turpie. MD, FRCP(C). Objectives. Interpret the Canadian Cardiovascular Society . presented by . Paul St. Laurent, MSN, RN, ACNP, CCRN. Acute Care Nurse Practitioner. Baylor Heart and Vascular Hospital. What Do We Already Know?. Aspirin reduces the risk of myocardial infarction. Antiplatelet therapy reduces stent thrombosis. Acute Coronary Syndromes and Diabetes. Chapter 26. Jean-Claude Tardif, Phillipe L. L’Allier,. David H. Fitchett. Acute Coronary Syndrome Checklist. SCREEN. for DM among patients with ACS. USE . anti-platelet therapies, . Ticagrelor. for Secondary Prevention: . Insights from PEGASUS-TIMI 54 Trial . Marc P. . Bonaca. , MD, MPH. on behalf of the . PEGASUS-TIMI 54 . Executive & Steering Committees and Investigators. Giuseppe . Biondi-Zoccai. , MD. Sapienza University . of. . Rome. , Italy. giuseppe.biondizoccai@uniroma1.it. Learning. . goals. Scope . of. the . problem. Prasugrel. Ticagrelor. Reconciling. the . presented by . Paul St. Laurent, MSN, RN, ACNP, CCRN. Acute Care Nurse Practitioner. Baylor Heart and Vascular Hospital. What Do We Already Know?. Aspirin reduces the risk of myocardial infarction. Antiplatelet therapy reduces stent thrombosis. Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group: Jean-François Tanguay , MD, CSPQ, FRCP(C), FACC, FAHA, FESC; Michael P. Love, MB, ChB, MD, MRCP; and Robert C. Welsh, MD, FRCP, FACC Associate Professor of Clinical Pharmacy,. SBMU. CLASSIFICATION OF ANTIPLATELET AGENTS. Cyclooxygenase inhibitors. Aspirin. Platelet . P2Y12 receptor . blockers. clopidogrel, . ticlopidine. , . ticagrelor. ORIGIN. Pierre . Amarenco. , Hans . Denison. , . Scott R. Evans, Anders . Himmelmann. , Stefan James, Mikael . Knutsson. , . Per . Ladenvall. , Carlos . A. Molina. , . Yongjun. Wang. , S. . Claiborne . Akhtar . Fajar. . Muzakkir. New ESC NSTEMI Guideline. Collet JP et al European Heart Journal (2020) 00, 1-79 . What is NEW?. Collet JP et al European Heart Journal (2020) 00, 1-79 . Major Changes in Recommendation. CrCl. : creatinine clearance, CTO: chronic total occlusion, DAPT: dual antiplatelet therapy, DOAC: direct oral anticoagulant, . eDAN. : electronic discharge advice notification, GFR: glomerular filtration rate, HF: heart failure, INR: international normalised ratio, LHP: Leeds Health Pathways, LTHT: Leeds Teaching Hospitals NHS Trust, LV: left ventricular, MACE: major adverse cardiovascular event, MI: myocardial infarction, NICE: National Institute for Health and Care Excellence, NSTEMI: non-ST segment elevation myocardial infarction, STEMI: ST segment elevation myocardial infarction, OD: once daily, PAD: peripheral arterial disease, P2Y12: platelet receptor for adenosine diphosphate PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, SPC: summary of product characteristics, TIA: transient ischaemic attack.. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. 1. ; Fabiana Rollini, MD1, Mattia Galli, MD. 1. ,. 2. Latonya Been, AAS. 1. , Ghussan Ghanem, MD. 1. , . Awss. . Shalhoub. , MD. 1. , Tiffany Ossi, MD. Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial. Gregg W Stone MD. Icahn School of Medicine at Mount Sinai. on behalf of Shao-Liang Chen and the ULTIMATE-DAPT Investigators. Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa . Wali. , MD, . Zubair. Shaikh, MD, . Maryuri. . Briceno. , MD, Ahmed Nawaz, MD, Jae Youn Moon, MD, . PhD, Latonya . Been, AAS, Siva Suryadevara, MD, Daniel Soffer, MD, Martin M Zenni, .